A Phase Ib / II Study to Evaluate the Efficacy and Safety of KC1036 in the Patients with Advanced Recurrent or Metastatic Digestive System Tumors
Latest Information Update: 22 Oct 2024
At a glance
- Drugs KC 1036 (Primary)
- Indications Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors KONRUNS Pharmaceutical
Most Recent Events
- 17 Oct 2024 Planned End Date changed from 30 Apr 2025 to 30 Dec 2025.
- 17 Oct 2024 Planned primary completion date changed from 30 Apr 2024 to 30 Oct 2025.
- 06 Jun 2023 Results (at data cut-off date December 30, 2022; n=58), for preliminary outcomes from a phase II study, presented at the 59th Annual Meeting of the American Society of Clinical Oncology